Antisense-oligonucleotides as inhibitors of tgf-r signaling
AssigneeNeuroVision Pharma GmbH
InventorsMARKUS HOSSBACH, MONIKA KRAMPERT, HANS-LOTHAR ARTH
Life of this patent
Estimating the term…
Abstract
The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
Claims22
1-21. (canceled)
An antisense-oligonucleotide consisting of 10 to 28 nucleotides and at least two of the 10 to 28 nucleotides are LNAs, wherein the antisense-oligonucleotide has a gapmer structure with 1 to 5 LNA units at the 3′ terminal end and 1 to 5 LNA units at the 5′ terminal end and the antisense-oligonucleotide hybridizes with a region of the gene encoding the TGF-RII or with a region of the mRNA encoding the TGF-RII, wherein the region of the gene encoding the TGF-RII or the region of the mRNA encoding the TGF-RII comprises the sequence TGGTCCATTC (Seq. ID No. 4), and the antisense-oligonucleotide comprises a sequence hybridizing with said sequence TGGTCCATTC (Seq. ID No. 4) and salts and optical isomers of said antisense-oligonucleotide, wherein the antisense-oligonucleotide inhibits the expression of TGF-RII.
Dependencies are inferred from the claim text.